


Organized in association with:




International Extranodal Lymphoma Study Group

and **“Fondazione per la Ricerca e la Cura dei Linfomi nel Ticino”**



13-ICML

13th International Conference on Malignant Lymphoma



**Preliminary Program
and Call for Abstracts**

JUNE 17-20, 2015
PALAZZO DEI CONGRESSI
LUGANO, SWITZERLAND

INDEX:

- 2 Contact details
- 3 Welcome - Organizing Committee & Advisory Board
- 4 General Information
- 7 Abstract submission
- 10 Registration
- 11 Group Registration
- 12 Hotel accommodation
- 13 Individual registration - Information & Registration Form
- 14 Provisional scientific program



ICML President:

Prof. Dr. F. Cavalli
IOSI Scientific Director
Tel: +41 91 811 86 66
Fax: +41 91 811 80 56
franco.cavalli@eoc.ch

Fondazione per la Ricerca e la Cura dei Linfomi nel Ticino

vat number: CHE-110.407.651 IVA
www.lymphomafoundation.ch



President Local Organizing Committee:

Prof. Dr. M. Ghielmini
IOSI Medical Director
Tel: +41 91 811 94 10
Fax: +41 91 811 87 31
michele.ghiellini@eoc.ch

IELSG

International Extranodal Lymphoma Study Group-Studies
Coordination Operation Office
Oncology Institute of Southern Switzerland
Ospedale San Giovanni
CH-6500 Bellinzona
www.ielsg.org

ICML Secretariat:

IOSI - Oncology Institute of Southern Switzerland
Ospedale San Giovanni, CH-6500 Bellinzona
Cristiana Brentan, Orietta Lugli, Chiara Saporiti
Tel: +41 91 922 05 75, Fax: +41 91 922 20 84
cristiana.brentan@lymphcon.ch, orietta.lugli@lymphcon.ch, registration@lymphcon.ch



SAVE THE DATE!
14-ICML: 14-17 June 2017

LOCAL ORGANIZING COMMITTEE

(based in Bellinzona, Switzerland):

F. Bertoni
 F. Cavalli – ICML President
 M. Ghielmini – President
 A. Moccia
 F. Peccatori – ESO, European School of
 Oncology representative
 A. Stathis
 G. Stüssi
 E. Zucca

ADVISORY BOARD:

J.O. Armitage, Omaha, NE (USA)
 E. Campo, Barcellona (Spain)
 B.D. Cheson, Washington, D.C. (USA)
 J.M. Connors, Vancouver (Canada)
 F.E. Cotter, London (UK)
 R. Dalla-Favera, New York, NY (USA)
 S. Dirnhofer, Basel (Switzerland)
 M. Dreyling, Munich (Germany)
 A. Engert, Cologne (Germany)
 M.F. Fey, Bern (Switzerland)
 J.W. Friedberg, Rochester, NY (USA)
 G. Gaidano, Novara (Italy)
 R. Gascoyne, Vancouver (Canada)
 P. Gaulard, Créteil (France)
 M.K. Gospodarowicz, Toronto (Canada)
 M. Hallek, Cologne (Germany)
 E.S. Jaffe, Bethesda, MD (USA)
 P.W.M. Johnson, Southampton (UK)
 R. Küppers, Essen (Germany)
 J.P. Leonard, New York, NY (USA)
 T. A. Lister, London (UK)
 A. Lopez-Guillermo, Barcelona (Spain)
 M.A. Piris, Santander (Spain)
 S.V. Rajkumar, Rochester, MN (USA)
 M. Seto, Nagoya (Japan)
 J.F. Seymour, Melbourne (Australia)
 M.A. Shipp, Boston, MA (USA)
 L. Specht, Copenhagen (Denmark)
 L.M. Staudt, Bethesda, MD (USA)
 C. Thieblemont, Paris (France)
 K. Tobinai, Tokyo (Japan)
 U. Vitolo, Turin (Italy)
 A. Younes, New York, NY (USA)
 W. Wösslmann, Giessen (Germany)

Welcome to Lugano

The 13th International Conference on Malignant Lymphoma, the most important international forum devoted to basic and clinical research in lymphoid neoplasms, will take place in June 2015. Basic and clinical data will be presented during the sessions, focused not on a specific morphologic subtype, but rather on pathways or other biological aspects (e.g. microenvironment, immune system, chromosomal abnormalities, etc.). New sessions, such as the Educational Symposia, the special sessions devoted to radiotherapy and the ongoing trials presentation, were introduced in 2013 and, thanks to the many positive feedbacks, they will be repeated. Immediately after the Kaplan Lecture, worldwide known experts will discuss the best 3-4 accepted abstracts during a **Plenary Session**.

We are convinced that the 13th ICML will attract again many scientists to Lugano... and not only for the scientific program! Lugano is in fact the largest city in Southern Switzerland and it is considered one of the most beautiful spots in Europe.

We invite the submission of high-quality abstracts on all aspects of lymphoid neoplasms, including multiple myeloma and CLL. Due to time constraints, only a limited number of abstracts can be selected for proffered papers (in the general sessions and in the "Focus on..." sessions). To assure a fair selection, all abstracts will be reviewed by at least 7 international experts.

The deadline for submitting abstracts is **February 28, 2015**, approximately three months before the conference. This very short interval should allow the inclusion of abstracts reporting the most recent results. The Abstract Book will also include an Educational Section with extended articles of all educational sessions.

We look forward to welcoming you to Lugano in June 2015.

Prof. Dr. F. Cavalli
 President ICML

Prof. Dr. M. Ghielmini
 President Local Organizing
 Committee

GENERAL INFORMATION

VENUE

The 13th International Conference on Malignant Lymphoma will take place in the Lugano Convention Centre, Palazzo dei Congressi, just near to the city park Parco Ciani.

Palazzo dei Congressi is in the centre of the city, at 10 minutes walking distance from the central railway station and 10 minutes by taxi from Agno, the local airport. Its rooms will host the scientific general sessions and the satellite symposia.


Due to Palazzo dei Congressi limited capacity, some of “Meet the Professor”, “Focus on...” and scientific parallel sessions will be held in additional large conference rooms at 5 minutes walking distance from the Convention Centre (e.g. Lugano University Campus).

As usual, lunches, coffee breaks and the commercial exhibition will take place in the “Marquee Parco Ciani”, a large gazebo built in the beautiful park surrounding Palazzo dei Congressi and bordering the lake of Lugano.

PARTICIPANT PROFILE

The 13-ICML will bring 3'000 physicians to Lugano from all over the world: haematologists, clinical oncologists, radio-oncologists, paediatricians, pathologists and leading researchers involved in the study and treatment of lymphoid neoplasms.

Demographics from 12-ICML (June 2013)... and a couple of pictures of ICML breaks!



12-ICML attendees (px): 2905, from 76 different countries



CONTINUING MEDICAL EDUCATION

Application for European CME accreditation (ECMEC) will be made to the European Union of Medical Specialties-European Accreditation Council for Continuing Medical Education (UEMS-EACCME®). European credits are recognised by the American Medical Association (AMA).

The 13-ICML program will be once again part of the Certificate of Competence in Lymphoma (CCL), a 14 months ECTS program developed by ESO and academically recognized by the Ulm University. The aim of the Certificate of Competence is to provide a curriculum of studies to advance knowledge and science in the management of lymphoma patients. The first CCL was successfully concluded in March 2014.

Further information can be obtained by visiting <http://www.eso.net/page-interne/ccl-introduction.html>



2015 Full Immersion Course on Leukaemia and Lymphoma

held in co-operation with the European School of Oncology (ESO)

Chairmen: J.O. Armitage (USA), M.F. Fey (Switzerland) and E. Zucca (Switzerland)

Hosting Chair: F. Cavalli (Switzerland)

Date: 13-16 June, 2015

Location: Monte Verità, Ascona (40 km from Lugano)

The international faculty will guide participants through the complexity of biology and important clinical problems in leukaemias and lymphomas, offering interactive case-presentations, small group seminars, and ample discussion slots. There will also be opportunities for informal exchange of ideas and views among the participants and the experts.

Attendance will be limited to 80 participants and registrations will be received on a first-come/first-served basis.

Further information can be obtained from the ESO Bellinzona Office (dknupfer@eso.net) or by visiting www.eso.net

INSURANCE

The 13-ICML Organizing Committee bears no responsibility for untoward events in connection with, before, during and after the congress. Participants are strongly advised to obtain their own personal and travel insurance coverage.

VISA

Citizens of some foreign countries will need a visa to enter Switzerland. An overview of visa provisions is available visiting www.lymphcon.ch - individual and group registration information.

Please note that only delegates who successfully complete their registrations to the conference can receive a Letter of Invitation to submit a visa application.

ITALIAN DELEGATES

Sponsors of Italian delegates who need an AIFA pre-request should address their requests to:

Barbara Mantegazza

Aria di Viaggi Srl - Congress and Fair Department

Via Matteo Bandello, 1 - 20123 Milano - Italy

Tel. +39 02 6693007

Fax +39 02 66716063

barbara.mantegazza@ariadiviaggi.it

ABSTRACT SUBMISSION

Abstracts for oral presentations, “Focus on...” sessions (see “Scientific program”) and poster sessions must be submitted online no later than **February 28, 2015** at www.lymphcon.ch. The decision on the abstract evaluation will be notified to the first author/presenter by April 15, 2015.

Abstracts can be related to all aspects of biology and treatment of lymphoid neoplasms.

As for the last ICML, abstracts on ongoing trials will be accepted if complying with specific conditions (see “Scientific program”).

ABSTRACT SUBMISSION POLICY AND REGULATIONS

The first author for each abstract serves as presenter and primary contact for all correspondence regarding the abstract.

Upon submission of an abstract, the first author/presenter is responsible for the following:

- ensuring that all authors have read the abstract and agreed to be co-authors;
- forwarding all correspondence regarding the abstract to all co-authors;
- releasing abstract copyrights to 13-ICML;
- giving permission to record his/her presentation at the 13-ICML Congress for multimedia coverage and release or sale to attendees;
- disclosing any actual, potential, or apparent conflict of interest, declaring the name of the company (s)he maintains a “relevant financial relationships”* with. Unless otherwise indicated, it is implied that there are no conflicts of interests pertinent to the abstract;
- obtaining all conflict-of-interest disclosure from co-authors;
- certifying that the same abstract has neither been nor will be previously published in any publication in peer review setting before the 13-ICML. Furthermore, the first author/presenter certifies that the study will not be presented as such during the 13-ICML at any satellite symposia.

*“*Relevant financial relationships*” are intended those from which the author or any individual with whom (s)he directly shares income has received or may receive financial benefit within the past 24 months. The relationships to declare are: employment or leadership position in a company – consultant or advisory role - stock ownership – honoraria – research funding – other remuneration.

During the online abstract submission, the following information will be required:

- First author/presenter complete contact details (first and middle name, surname, department, affiliation, mailing address, city and country, telephone and fax number, e-mail address), for future correspondence and notification on the abstract evaluation outcome;
- Co-authors' first and middle name initials, surname, department, affiliation, city and country.
- Preference of presentation: Oral presentation (including “Focus on...” sessions) or Poster presentation; anyway the final decision on the presentation format will be made by the Organizing Committee.

NB:

Changes of the option of withdrawal are not possible after the submission deadline.

- Abstract eligibility for session on Ongoing trials (please check “Scientific program” for conditions).
- Option of withdrawal of the abstract in case of selection for publication only in the Abstract and Educational Book.
- Application for a travel award, in case the abstract is selected for presentation. The applicant must be first author/presenter of the abstract and aged 35 years or younger.
- Keywords (min. 1 – max. 4), to be selected from the list available online.
- Acceptance of abstract submission policy and regulations including first author/presenter responsibilities and in particular:
 - 1) release of copyright and permission to multimedia recording of presentation;
 - 2) disclosure of conflict of interest;
 - 3) no prior publication of the same abstract in any publication in peer review setting - no presentation of the same abstract, during the conference, at any satellite symposia.
 - 4) withdrawal policy: abstracts selected for oral or poster presentation must be presented. Abstract withdrawal requests cannot be accepted. If the presenting author cannot attend, (s)he should assign a replacement and inform ICML Secretariat (Cristiana.brentan@lymphcon.ch) of the replacement as soon as possible.

GUIDELINES FOR ABSTRACT PREPARATION

- Abstracts must not be longer than 2'500 characters (text and table included; title, authors' list and spaces not included).
Only one data table is permitted in the text of the abstracts. Illustrations or figures are not accepted. The table counts for 350 characters.
- The title must not exceed 150 characters (spaces not included).
- The number of listed co-authors must be limited to twenty-five.
First author/presenter name must be underlined. All authors will be listed with first and middle name initials, surname, department, affiliation, city and country.
Please note that, in order for affiliations to be grouped properly, the exact same information for affiliation, department, city, and country fields must be entered.
- Abstracts should include the following 4 sections: **Introduction, Methods, Results, Conclusions** (these headers should be in bold and sentence case, as shown here).
- Compounds should be mentioned with the generic name in lower case. Commercial names may not be used in the title of the abstract. Commercial names are admitted in the text, in brackets and with the © symbol, following the generic name, i.e. 'generic (Commercial©)'.
- Names of cooperative study groups should appear in the title, as they can not be included in the authors' list.

EDUCATIONAL AND ABSTRACT BOOK

All selected abstracts will be included in the Abstract Book distributed to attendees on site and available online as of Wednesday, June 10, 2015. An Educational section including summaries of the Educational sessions will be added to the Abstract Book.

IMPORTANT:

the submission of an abstract does not automatically imply registration to the conference. Abstract presenters must register to attend the 13-ICML.

TRAVEL AWARDS



krebsliga schweiz
ligue suisse contre le cancer
lega svizzera contro il cancro

A limited number of travel awards sponsored by the Swiss Cancer League will be provided to young investigators (less than 35 years), whose abstract has been accepted for oral presentation.

Some of 12-ICML Post-ICML events:

*Tokyo, Japan,
03 August, 2013*



*Riyadh,
Saudi Arabia,
19 September 2013*



*Seoul, Korea,
05 October, 2013*



REGISTRATION

Due to space restrictions, attendance will be limited to a maximum number of 3000 attendees.

Registrations will be closed as soon as the first 3000 paid registrations have been obtained.

Application to participate in the 13-ICML can be made online at www.lymphcon.ch

Alternatively, the enclosed registration form should be filled in and sent to:

ICML Secretariat
Oncology Institute of Southern Switzerland (IOSI)
Ospedale San Giovanni, CH - 6500 Bellinzona, Switzerland
Fax +41 (0)91 922 20 84

together with the copy of the wire transfer.

REGISTRATION FEE

- EARLY registration:
on or before March 13, 2015 Swiss Francs 1000.-
- LATE registration:
from March 14, 2015 (**up to 3'000 attendees**) Swiss Francs 1200.-

The full registration fee will cover access to the scientific sessions and Exhibition, a copy of the Educational and Abstract Book, three lunches and refreshment breaks and the Farewell Aperitif on Friday, June 19, 2015.

Every registered participant will receive a complimentary ticket valid for public transportation in the city of Lugano as well as in the Ticino region.

Complimentary transfers will be available at scheduled times from and to hotels booked through Amiconi Consulting and not reached by public transportation.

PAYMENT INFORMATION

Full payment of the online registration fee can be settled by credit card (American Express, VISA or MasterCard - online encrypt transaction).

Alternatively, the proof of the payment must reach the ICML Secretariat together with the enclosed registration form.

The **wire transfer**, with no costs to the beneficiary, should be made to:

Account holder:	Fondazione per la Ricerca e la Cura dei Linfomi
Account name:	ICML
Account number:	336 9742/001.001.001
Bank:	Banca dello Stato del Canton Ticino via Pioda 7, 6900 Lugano, Switzerland
IBAN CODE:	CH47 0076 4336 9742 C001 C
SWIFT:	BSCTCH22LUG - clearing no. 00764

The name of the participant should be clearly stated on the bank transfer.

Please note that no registrations will be processed without payment.

CANCELLATION POLICY

Name changes or cancellations will only be accepted in writing. Refund of the registration fee (less 20% administration fee), will be granted if notification of cancellation reaches the 13-ICML Secretariat on or before Friday, May 22, 2015. Refunds from cancelled registrations will be processed after the conference.

GROUP REGISTRATION (minimum: 10 participants)

Summary of the deadlines for Group Registration:

Payment of early fees (no-name registrations CHF 1000.- each)	March 13, 2015
Participants list (names and addresses)	May 22, 2015
Collection of the material	from June 15, 2015

Group Registrations benefit from the early registration fee when the payment is received by the 13-ICML Secretariat on or before **March 13, 2015**. After this date, payment of late registration fee (CHF 1200.-) is required.

Group administrators should complete the group registration form online specifying the number of no-name registrations, group name, the preferred method of payment (credit card or bank transfer) and housing information (booking source, booked rooms number and hotel name should be provided).

Once the payment is settled, the group administrator will receive username and password to include the required personal data of each participant in the conference database.

Group administrators must provide complete information on each participant (including the full address of the institute and the personal e-mail address).


The participants' list must be received by the 13-ICML Secretariat by May 22, 2015.

From May 23, 2015, a penalty fee of CHF 200.- will be charged for each name not yet provided and for each name change.

Group registration fees are not refundable.

Congress materials for groups will be available for pick up at preassigned times on Monday June 15, 2015, at the Registration Desk in Palazzo dei Congressi main hall.

Please ask for an appointment sending an e-mail to registration@lymphcon.ch.



HOTEL ACCOMMODATION

Booking of hotel accommodation should be made contacting:

Amiconi Consulting
Via al Forte 10
CH-6900 Lugano, Switzerland
Tel: +41 (0)91 921 38 12
Fax: +41 (0)91 921 38 13
e-mail: info@amiconiconsulting.ch
www.amiconiconsulting.ch

Due to heavy room demand, early booking is advisable in order to arrange proper accommodation.

All efforts will be made to assign hotel rooms according to the participants' choice. However, should this not be possible, alternative category and/or location will be provided.

TRAVEL ARRANGEMENTS - PRIVATE TRANSFER SERVICES

Lugano is situated on the main north-south axis in Europe, both with regards to roads as well as train connections; it can therefore be easily reached either from Milan and Como (1 hour), or from Zurich or Basel (3 hours).

Agno, Lugano's airport, is linked to most European cities directly, or via Basel, Zurich and Geneva airports.

Bus connections to and from Milan airports (Malpensa and Linate) are available.

Amiconi Consulting can be contacted to arrange private transfer services (from and to the airports of Milano Linate, Malpensa, Orio al Serio & Lugano and in the city of Lugano and its surroundings), for both individuals and groups.

OFFICIAL CARRIER



Official Carrier

Swiss International Air Lines is proud to be the Official Carrier for the 13-ICML and is offering special congress fares to all participants. These Congress Fares offer reductions of up to 25% depending on the fare type, route and space availability.

Congress fares are valid on the entire SWISS route network for flights to Switzerland, including flights operated by partner airlines under an LX flight number.

On-line reservations will become available on August 1, 2014.

These fares will be bookable for the travel period 14 days prior to and 14 days after the event.

To take advantage of this offer, book easily and conveniently through SWISS.COM via the following link: www.swiss.com/event

Due to legal reasons, the event code can not be published, therefore it will be included in the official 13-ICML Confirmation of registration.

SWISS looks forward to pampering you on board with typical Swiss hospitality.



REGISTRATION FORM

To be returned with proof of payment (copy of the wire transfer) to:

ICML Secretariat
Oncology Institute of Southern Switzerland (IOSI)
Ospedale San Giovanni, CH - 6500 Bellinzona, Switzerland
Fax +41 (0)91 922 20 84

PLEASE COMPLETE (typewrite or capital letters):

Prefix: Mr. Mrs. Dr. Prof. other:

Last name: _____ **First name:** _____

Affiliation: _____

Department: _____

Street address: _____

City: _____ **Postal code:** _____ **Country:** _____

Phone: _____ **Fax:** _____

E-mail: _____

BILLING ADDRESS (if different from above and if invoice is necessary):

Last name: _____ **First name:** _____

Affiliation: _____

Department: _____

Street address: _____

City: _____ **Postal code:** _____ **Country:** _____

REGISTRATION FEE:

- Swiss Francs 1'000.- EARLY registration: on or before March 13, 2015
 Swiss Francs 1'200.- LATE registration: from March 14, 2015 (**up to 3'000 attendees**)

PAYMENT PROCEDURE:

Wire transfer, with no costs to the beneficiary, to:

Account holder:	Fondazione per la Ricerca e la Cura dei Linfomi
Account name:	ICML
Account number:	336 9742/001.001.001
Bank:	Banca dello Stato del Canton Ticino, via Pioda 7, 6900 Lugano, Switzerland
IBAN CODE:	CH47 0076 4336 9742 C001 C
SWIFT:	BSCTCH22LUG - clearing no. 00764

Please, clearly state the name of the participant on the bank transfer!

PROVISIONAL SCIENTIFIC PROGRAM

Based on the abstracts received and accepted for oral presentation, general sessions 1-13 will be devoted to either specific subtypes of lymphoid neoplasia (e.g. mantle cell lymphomas, follicular lymphomas, T-cell lymphomas, etc), or to the presentation of laboratory and clinical research data grouped around a biologic topic (for example, microenvironment, signalling pathway, surface antigens). The latter sessions will be introduced by an expert summarizing the topic.

“**Focus on...**” are parallel oral sessions highlighting abstracts of scientific value but not selected for oral presentation during the general sessions. These sessions will be run in parallel and each will be focused on a particular topic. The one-hour sessions will consist of six presentations of 10 minutes each, including discussion.

Clinical discussion sessions have presenters of outstanding centers addressing cases which are not trivial nor very rare, but rather situations commonly encountered but the solution of which remains controversial. In 2013 we experienced a US vs. Europe debate (Mayo Clinic vs. Lysa), in 2015 again we will have New York and FIL (the cooperative Italian Lymphoma Foundation).

Special sessions devoted to **radiotherapy**, organized in collaboration with ILROG (International Lymphoma Radiation Oncology Group): two satellite workshops will take place on Tuesday afternoon, open to all 13-ICML attendees. Further details will follow.

Furthermore, a special session on “Contouring in Modern Lymphoma Radiotherapy Planning” will be held on Saturday June 20, 08:00 – 10:30, for max. 30 lymphoma radiation oncologists (pre-registration at registration@lymphcon.ch is necessary).

Extra space for **pediatric oncology**: besides the usual general session we will have a “Meet the Professor” session and a Clinical case discussion devoted to pediatric oncology. Should there be a sufficient amount of abstracts considered interesting for the overall audience of ICML, a “Focus on pediatric lymphomas” session will be added to the program. Pediatric abstracts will be eligible also for the Plenary session.

Ongoing trials presentation: this session will comprise abstracts describing ongoing trials. Conditions for being selected for presentation at this session are:

- enrolment has already started,
- accrual of new patients is still possible.

The session should not be regarded as an advertisement for new drugs. Trials which are close to completion (i.e. not available for other possible participants) and closed trials will not be considered for presentation.

Educational symposia (parallel sessions)

- Histological transformation in Lymphoma

Speakers: John G. Gribben, London (UK) - chair, Randy Gascoyne, Vancouver, BC (Canada) and Davide Rossi, Novara (Italy)

- Hodgkin Lymphoma

Speakers: Ranjana Advani, Stanford, CA (USA) - chair, Andreas Engert, Cologne (Germany) and John Radford, Manchester (UK)

Key Note Lectures

- Henry Kaplan Memorial Lecture, linked to San Salvatore Prize (sponsored by Fondazione San Salvatore)

The speaker and awardee will be selected during 2014.

- Henry Rappaport Memorial Lecture

Mantle cell lymphoma, an unfolding story from the microscope to the genome
Elias Campo, Barcelona (Spain)

- John Ultmann Memorial Lecture (sponsored by European School of Oncology)

Cutaneous lymphomas: past, present and future
Rein Willemze, Leiden (The Netherlands)

13-ICML Highlights

“Take home messages”

James O. Armitage, Omaha, NE (USA)



A Hospitality Suite in Villa Ciani

PROVISIONAL LIST OF MEET THE PROFESSOR SESSIONS:

1. Hodgkin Lymphoma: Special Challenges and Solutions
Joseph M. Connors, Vancouver, B.C. (Canada)
2. Challenges in the management of PTLTD
Gianluca Gaidano, Novara (Italy)
3. Current Concepts in Primary Central Nervous Lymphoma
Gerald Illerhaus, Stuttgart (Germany)
4. Masses in the mediastinum: primary mediastinal lymphoma and intermediate types
Peter M.W. Johnson, Southampton (UK)
5. Smoldering Multiple Myeloma
Maria-Victoria Mateos, Salamanca (Spain)
6. PET as a biomarker in lymphoma:
from qualitative to quantitative analysis
Michel Meignan, Creteil (France)
7. Are lymphomas driven by epigenetic lesions?
Ari M. Melnick, New York, NY (USA)
8. Treatment of CLL, where are we heading?
Susan M. O'Brien, Houston, TX (USA)
9. Is it only about MYC? How to approach the diagnosis of Diffuse Large B-cell Lymphomas
Leticia Quintanilla de Fend, Tübingen (Germany)
10. Peripheral T-cell Lymphomas: Challenges and Future Directions
Kerry Savage, Vancouver, B.C. (Canada)
11. Pediatric Lymphoma
Wilhelm Wössmann, Giessen (Germany) – TBC
12. New approaches to therapy, including Checkpoint blockade (PD-1 and CTLA-4 inhibition) and CAR T-cell therapy
Anas Younes, New York, NY (USA)



Wednesday, June 17

	Room A	Room B	Room C	Marquee	Cinema	Uni Aud	Uni Magna
7:30	OPENING HOURS OF THE REGISTRATION DESK: 07:30 - 19:30 / EXHIBITION AREA OPENING HOURS: 08:30 - 18:30						
8:00				<i>POSTERS Set Up (posters displayed until Friday, 18:30)</i>			
8:15							
8:30	Meet the Professor (08:30-09:15)	Meet the Professor (08:30-09:15)			Meet the Professor (08:30-09:15)	Meet the Professor (08:30-09:15)	Meet the Professor (08:30-09:15)
8:45							
9:00							
9:15							
9:30	Meet the Professor (09:30-10:15)	Meet the Professor (09:30-10:15)			Meet the Professor (09:30-10:15)	Meet the Professor (09:30-10:15)	Meet the Professor (09:30-10:15)
9:45							
10:00				COFFEE			
10:30							
10:45				Educational symposium room A (10:35-12:00)			
11:00							
11:15							
11:30							
11:45							
12:00							
12:15				LUNCH and Poster Viewing			
12:30							
12:45							
13:00							
13:15							
13:30	Opening of the Conference and Henry Kaplan Memorial Lecture (13:00- 13:55) room A - B - marquee			Kaplan Lecture (13:00-13:55)			
13:45							
14:00							
14:15							
14:30							
14:45							
15:00							
15:15							
15:30				PLENARY SESSION (14:00-15:30)			
15:45				COFFEE			
16:00							
16:15							
16:30							
16:45							
17:00							
17:15							
17:30	"Focus on..." session (17:15-18:15)	"Focus on..." session (17:15-18:15)	"Focus on..." session (17:15-18:15)		"Focus on..." session (17:15-18:15)	"Focus on..." session (17:15-18:15)	"Focus on..." session (17:15-18:15)
17:45							
18:00							

Thursday, June 18

Thursday, June 18						
Room A	Room B	Room C	Marquee	Cinema	Uni Aud	Uni Magna
OPENING HOURS OF THE REGISTRATION DESK: 07:30 - 19:30/ EXHIBITION AREA OPENING HOURS: 08:30 - 18:30						
7:30						
7:45						
8:00	Meet the Professor (08:00-08:45)				Meet the Professor (08:00-08:45)	Meet the Professor (08:00-08:45)
8:15						
8:30						
8:45						
9:00	SESSION 2: CLL BIOLOGY (09:00-10:30) room A - marquee	Clinical case discussion: PEDIATRIC AND ADOLESCENT LYMPHOMAS (09:00-10:30)	SESSION 2 (09:00-10:30) room A - marquee	Clinical case discussion: T-CELL LYMPHOMAS (09:00-10:30)	Clinical case discussion: MULTIPLE MYELOMA (09:00-10:30)	Clinical case discussion: HODGKIN LYMPHOMAS (09:00-10:30)
9:15						
9:30						
9:45						
10:00						
10:15						
10:30						
10:45			COFFEE			
11:00	SESSION 3: ADVANCES IN THE CLINICAL MANAGEMENT OF CLL room A - B - marquee (10:50-12:00)		SESSION 3 (10:50-12:00)			
11:15						
11:30						
11:45						
12:00			LUNCH and Poster Viewing			
12:15						
12:30						
12:45						
13:00	Henry Rappaport Lecture room A - B - marquee (13:00 - 13:45)		Rappaport Lecture			
13:15						
13:30						
13:45						
14:00	SESSION 4: FOLLICULAR LYMPHOMA room A - B - marquee (13:50 - 15:15)		SESSION 4 (13:50 - 15:15)			
14:15						
14:30						
14:45						
15:00			COFFEE			
15:15						
15:30	SESSION 5: TARGETING THE BCR-NFkB PATHWAYS (15:35-17:00)	SESSION 7: PEDIATRIC LYMPHOMA (15:35-18:00)	SESSION 5 (15:35-17:00)			
15:45						
16:00						
16:15						
16:30						
16:45						
17:00						
17:15	"Focus on..." session (17:15-18:15)			"Focus on..." session (17:15-18:15)	"Focus on..." session (17:15-18:15)	"Focus on..." session (17:15-18:15)
17:30						
17:45						
18:00						



Friday, June 19

Saturday, June 20

Room A		Room B		Room E		Marquee		Cinema		Exhibition Area		Uni Aud		Uni Magna	
OPENING HOURS OF THE REGISTRATION DESK: 07:30 – 19:30 / EXHIBITION AREA OPENING HOURS: 08:30 – 18:30															
7:30															
7:45															
8:00	Meet the Professor (08:00-08:45)	Meet the Professor (08:00-08:45)						Meet the Professor (08:00-08:45)	Meet the Professor (08:00-08:45)	Meet the Professor (08:00-08:45)					
8:15															
8:30															
8:45															
9:00	SESSION 8: TARGETING THE LYMPHOMA EPIGENOME (09:00-10:30) room A - marquee	Clinical case discussion: AGGRESSIVE LYMPHOMAS (09:00-10:30)						Clinical case discussion: CLL (09:00-10:30)	Clinical case discussion: EXTRANODAL LYMPHOMAS (09:00-10:30)	Clinical case discussion: MCL (09:00-10:30)					
9:15															
9:30															
9:45															
10:00															
10:15															
10:30															
10:45															
11:00															
11:15															
11:30	SESSION 9: DLBCL TREATMENT STRATEGIES room A - B - marquee (10:50-12:00)														
11:45															
12:00															
12:15															
12:30															
12:45															
13:00															
13:15															
13:30	John Ultsmann Memorial Lecture room A - B - marquee (13:00 - 13:50)														
13:50															
13:45															
14:00															
14:15															
14:30															
14:45															
15:00	SESSION 10: FRONT-LINE TREATMENT OF HODGKIN'S LYMPHOMA room A - B - marquee (14:00-15:15)														
15:15															
15:30															
15:45															
16:00	CONTROVERSY (15:35 - 16:15) room A - B - marquee														
16:15															
16:30															
16:45															
17:00	PRESENTATION OF ONGOING TRIALS (16:15-17:35) room A-B-Marquee														
17:15															
17:30															
17:45															
18:00															
18:15															
19:00-20:00 – IOSJ point counter point debate															



*Committed to improving
the lives of patients worldwide*